Last reviewed · How we verify
celecoxib, esomeprazole
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing inflammation and pain. Esomeprazole is a proton pump inhibitor that reduces stomach acid production.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing inflammation and pain. Esomeprazole is a proton pump inhibitor that reduces stomach acid production. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease.
At a glance
| Generic name | celecoxib, esomeprazole |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Drug class | NSAID, PPI |
| Target | COX-2, H+/K+ ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology, Pain management |
| Phase | Phase 3 |
Mechanism of action
Celecoxib works by blocking the action of COX-2 enzymes, which are involved in the production of prostaglandins that cause inflammation and pain. Esomeprazole, on the other hand, works by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby reducing gastric acid secretion.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
Common side effects
- Gastrointestinal upset
- Headache
- Diarrhea
- Nausea
Key clinical trials
- Opiate Sparing Protocol Randomized Controlled Trial in Open Distal Radius Fracture Repair (NA)
- Opiate Sparing Versus Opiate Based Following Shoulder Arthroplasty (NA)
- Efficacy and Safety of Chuna Manual Treatment as an Adjunctive Therapy After Total Knee Arthroplasty: A Study Protocol for a Single-Center, Randomized, Assessor Blind, Parallel-Group Clinical Trial (PHASE2)
- YouScript IMPACT Registry
- Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients (PHASE3)
- Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty? (PHASE2)
- Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis (PHASE4)
- Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- celecoxib, esomeprazole CI brief — competitive landscape report
- celecoxib, esomeprazole updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI